 Tiziana Life Sciences Ltd NASDAQ:TLSA has announced that Brigham and Womens Hospital BWH will receive a grant to explore the use of intranasal anti-CD3 monoclonal antibody mAb in the nervous system disease Amyotrophic Lateral Sclerosis ALS. The company said the Lawrence Isabel Barnett Drug Development Program Grant will be awarded to the Ann Romney Center for Neurologic Diseases at BWH by the ALS Association for the study of an intranasal anti-CD3 mAb in an animal model of ALS. 